C4 Therapeutics, Inc. CCCC
3.10 USD +0.15 (+5.08%)
At closeNov 9, 2026, 5:27 AM EST
3.00 -0.10 -3.21%
Pre-market · Nov 9, 5:27 AM ET
2.95 Day range 3.20
1.69 52-week range 5.17
- YTD
- +62.30%
- 1 year
- +30.25%
News
benzinga.com Guggenheim Maintains Buy on C4 Therapeutics, Lowers Price Target to $6 Guggenheim analyst Michael Schmidt maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and lowers the price target from $7 to $6.
zacks.com C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.44 per share a year ago.
benzinga.com C4 Therapeutics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $8.468M Miss $8.514M Estimate C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 63.64 percent increase over losses of…
globenewswire.com C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide…
globenewswire.com C4 Therapeutics to Participate in Upcoming November Investor Conferences WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)…
globenewswire.com C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,…
benzinga.com Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11 Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
benzinga.com JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10 JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.